Press Releases

MAKING THE PRESS

Runway for Hope: Lynn Lentscher's Speech

Runway for Hope: Lynn Lentscher's Speech

The Be the Difference Foundation presented Runway for Hope, a luncheon and fashion show benefiting Mary Crowley Cancer Research on September 26th. This speech was given by Be the Difference co-founder, Runway for Hope co-chair, and ovarian cancer survivor Lynn Lentscher. 

Be the Difference Foundation Announces Runway for Hope: A Luncheon and Fashion Show Benefiting Mary Crowley Cancer Research

Be the Difference Foundation Announces Runway for Hope: A Luncheon and Fashion Show Benefiting Mary Crowley Cancer Research

Join Be the Difference Foundation for their inaugural luncheon and fashion show, Runway for Hope, benefitting Mary Crowley Cancer Research, Thursday, September 26, 2019, from 11:30 AM to 1:30 PM at Arlington Hall, 3333 Turtle Creek Boulevard, Dallas, TX 75219.

Tempus and Mary Crowley Join Forces to Take On Lung Cancer

Tempus and Mary Crowley Join Forces to Take On Lung Cancer

Tempus most recently established a collaboration with Mary Crowley Cancer Research with the objective of expanding research options for lung cancer patents. As part of the collaboration, Tempus will be a preferred provider for Mary Crowley Cancer Research to perform molecular sequencing, analysis and provide clinical support for patients diagnosed with lung cancer.

Announcing Ashley E. Ross, M.D., PHD, Press Release

Announcing Ashley E. Ross, M.D., PHD, Press Release

The Board of Mary Crowley Cancer Research is delighted to announce the appointment of Ashley E. Ross, M.D., PhD, as Executive Medical Director. Dr. Ross brings a strong research background and outstanding leadership skills to direct Mary Crowley’s patient care and research initiatives.

FDA News Release

FDA News Release

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

Celebrating 20 Years